Immunological intervention to preserve beta-cell function in type 1 diabetes;Immunintervention zum betazellerhalt bei typ-1-diabetes

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 18, 2010, Pages 915-921

  Schloot, N C ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Beta cell function; Immunomodulation; Type 1 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTIOXIDANT; ATORVASTATIN; BCG VACCINE; CORTICOSTEROID; CYCLOSPORIN; DIAZOXIDE; FLAVONOL; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN; INSULIN LISPRO; OTELIXIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROQUINIMEX; TEPLIZUMAB; UNCLASSIFIED DRUG;

CELL FUNCTION; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; PLASMAPHERESIS; PRIMARY PREVENTION; PUVA; REVIEW; SECONDARY PREVENTION; STEM CELL TRANSPLANTATION; TERTIARY HEALTH CARE;

AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INSULIN-SECRETING CELLS;

EID: 77951823530     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1253678     Document Type: Review

References (38)

1. Barker J M., Liu E. Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv Pediatr 2008 55 349-65
2. Bonifacio E, Achenbach P, Pan L, Ziegler A G. Mucosal insulin vaccination for type 1 diabetes prevention. Exp Clin Endocrinol Diabetes 2008 116, Suppl 1 S26-29
3. Couri C E., Oliveira M C., Stracieri A B., Moraes D A., Pieroni F, Barros G M., Madeira M I., Malmegrim K C., Foss-Freitas M C., Simes B P., Martinez E Z., Foss M C., Burt R K., Voltarelli J C. Hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. J Am Med Assoc 2009 301 1573-1579
4. Diabetes prevention trial study grout DPT 1. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002 346 1685-1691
5. Ehehalt S, Blumenstock G, Willasch A M. et al. Continuous rise in incidence of childhood Type 1 diabetes in Germany. Diabet Med 2008 25 755-757
6. Eisenbarth G S. Type 1 Diabetes mellitus, A chronic autoimmune disease. N Engl J Med 1986 341 1360-1368
7. Eisenbarth G S., Jeffrey J. The natural history of type 1A diabetes. Arq Bras Endocrinol Metabol 2008 52 146-155
8. Elias D, Cohen I R. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes 1995 44 1132-1138
9. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000 355 873-876
10. Feltbower R G., Bodansky H J., Patterson C C., Parslow R C., Stephenson C R., Reynolds C, McKinney P A. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care 2008 31 922-926
11. Fourlanos S, Varney M D., Tait B D. et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008 31 1546-1549
12. Gale E A., Bingley P J., Emmett C L., Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetesLancet 2004 363 925-931
13. Gottlieb P A., Eisenbarth G S., Harrsion L, Colman P, Roep B, Quan J, Sovason N, Steinman L, Garren H, BHT-3021 Study Group. Interimresults of a phase I/II clinical trial of a DNA plasmid vaccine (BHT3021) for type 1 diabetes. Diabetologia 2009 52, suppl 1 S83, Abstract 188
14. Greenbaum C J., Mandrup-Poulsen T, McGee P F., Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin J M., Kolb H, Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group (Schloot N). Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008 31 1966-1971
15. Haller M J., Wasserfall C H., McGrail K M., Cintron M, Brusko T M., Wingard J R., Kelly S S., Shuster J J., Atkinson M A., Schatz D A. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009 32 2138-2139
16. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008 371 1777-1782
17. Herold K C., Gitelman S E., Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan D M., Bluestone J A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005 54 1763-1769
18. Huurman V A., Decochez K, Mathieu C, Cohen I R., Roep B O. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007 23 269-275
19. Jörns A, Akin M, Taivankhuu, Meyer zu Vilsendorf A, Lenzen S. Protection of the beta cell function by treatment with a rat specific CD3 antibody alone or in combination iwht the immunomodulatory agent FTY720 in the IDDM rat, an animal modle of human type 1 diabetes. Diabetologia 2009 52, Suppl 1 S198, Abstract 495
20. Kempf K, Manzo G, Hanifi-Moghaddam P, Kappler S, Seissler, Jaeger C, Boehm B, Roden M, Kolb H, Martin S, Schloot N C., for the PRODIAB Study Group. Effect of combined oral proteases and flavonoid treatment in subjects at risk for type 1 diabetes. (letter) Diabet Med 2009 26 1309-1310
21. Keymeulen B, Vandemeulebroucke E, Ziegler A G., Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin J M., De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach J F., Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005 352 2598-2608 (Pubitemid 41007846)
22. Lammi N, Blomstedt P A., Moltchanova E et al. Marked temporal increase in the incidence of type 1 and type 2 diabetes among young adults in Finland. Diabetologia 2008 51 897-899
23. Larsen C M., Faulenbach M, Vaag A, VOlund A, Ehses J A., Seifert B, Mandrup-Poulsen T, Donath M Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007 356 1517-1526
24. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007 23 286-291
25. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson N O., Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008 359 1909-1920
26. Martin S, Herder C, Schloot N C., Heise T, Heinemann L, Kolb H, DIATOR study group. Preservation of residual beta cell function in newly diagnosed type 1 diabetes by treatment with atorvastatin: the DIATOR trial. 2009 52, suppl 1 S199, Abstract 496
27. Mastrandrea L, Yu J, Behrens T et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009 32 1244-1249
28. Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care 2009 32 1563-1569
29. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä J I., Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008 372 1746-1755
30. Pfleger C, Mortensen H B., Hansen L, Herder C, Roep B O., Hoey H, Aanstoot H J., Kocova M, Schloot N C., ON BEHALF OF THE HVIDORE STUDY GROUP ON CHILDHOOD DIABETES. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008 57 929-937
31. Pickersgill L M., Mandrup-Poulsen T R., on behalf of the AIDA study group. The anti-interleukin-1 in type 1 diabetes action trial background and rationale. Diabetes Metab Res Rev 2009 25 321-324
32. Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen I R., Elias D. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function. Diabetes Metab Res Rev 2007 23 292-298
33. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen I R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277). Lancet 2001 358 1749-1753
34. Rother K I., Brown R J., Morales M M., Wright E, Duan Z, Campbell C, Hardin D S., Popovic J, McEvoy R C., Harlan D M., Orlander P R., Brod S A. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care 2009 32 1250-1255
35. Schloot N C., Meierhoff G, Lengyel C, Vandorfi G, Takacs J, Panczel P, Barkai L, Madacsy L, Oroszlan T, Kovacs P, Suto G, Battelino T, Hosszufalusi N, Jermendy G. Effect of heat shock protein peptide DiaPep277 on ß-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1. Diabetes Metab Res Rev 2007 23 276-285
36. Schloot N C., Roep B O. Islet antigen-specific T cell clones in autoimmune diabetes: from mice to men. Diabetes Metab Rev 1997 13 127-138
37. Steffes M W., Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003 26 832-836
38. Zipitis C S., Akobeng A K. Vitamin D supplementation in early childhood and risk of type 1 diabetes. Arch Dis Child 2008 93 512-517